All In Biotech

Drug Trial Radar · NCT07901725

Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis

An Open-Label, Randomized Phase 3 Trial of Linvoseltamab Compared With Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Participants With Newly Diagnosed Systemic Light Chain Amyloidosis

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 382 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

382

Planned (sponsor's estimate)

Start

Dec 18, 2026

Primary completion

Jul 25, 2035

Study completion Jul 25, 2035

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Oct 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching a Regeneron drug called linvoseltamab ("study drug") alone compared to standard of care (SoC) combination to see if it can help treat participants who are newly diagnosed and previously untreated for systemic amyloid light-chain (AL) amyloidosis. The aim of this study is to see if the safety and efficacy of linvoseltamab alone can deliver better disease control and outcomes than Dara-VCd. The study is looking at: * What side effects linvoseltamab alone might cause * How well linvoseltamab works compared to Dara-VCd regimen in terms of reductions of the abnormal proteins that cause AL-amyloidosis that affects the heart and kidney functions and for how long * How much linvoseltamab is in the blood at different times * Whether the body makes antibodies against linvoseltamab (which could make the drug less effective or could lead to side effects)

Conditions

  • Newly Diagnosed Amyloidosis
  • Amyloidosis Stage I-IIIA

Interventions

  • LinvoseltamabDrug

    Administered per the protocol

  • DaratumumabDrug

    Administered per the protocol

  • BortezomibDrug

    Administered per the protocol

  • CyclophosphamideDrug

    Administered per the protocol

  • DexamethasoneDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 7 years
  2. Severity of TEAEsTime frame: Up to 7 years
  3. Occurrence of Adverse Events of Special Interest (AESI)Time frame: Up to 7 years
  4. Severity of AESITime frame: Up to 7 years
  5. Occurrence of Serious Adverse Events (SAEs)Time frame: Up to 7 years
  6. Severity of SAEsTime frame: Up to 7 years
  7. Achievement of Hematologic Complete Response (HemCR) per International Society of Amyloidosis (ISA) response criteria as determined by Blinded Independent Review Committee (BIRC)Time frame: Up to 7 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.